580 related articles for article (PubMed ID: 15542651)
1. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
2. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
3. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.
Szabo I; Wetzel MA; Zhang N; Steele AD; Kaminsky DE; Chen C; Liu-Chen LY; Bednar F; Henderson EE; Howard OM; Oppenheim JJ; Rogers TJ
J Leukoc Biol; 2003 Dec; 74(6):1074-82. PubMed ID: 12972507
[TBL] [Abstract][Full Text] [Related]
4. Cyclic zinc-dithiocarbamate-S,S'-dioxide blocks CXCR4-mediated HIV-1 infection.
Takamune N; Misumi S; Shoji S
Biochem Biophys Res Commun; 2000 Jun; 272(2):351-6. PubMed ID: 10833417
[TBL] [Abstract][Full Text] [Related]
5. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
6. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
7. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4.
Boutet A; Salim H; Taoufik Y; Lledo PM; Vincent JD; Delfraissy JF; Tardieu M
Glia; 2001 May; 34(3):165-77. PubMed ID: 11329179
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection.
Gouwy M; Struyf S; Berghmans N; Vanormelingen C; Schols D; Van Damme J
Eur J Immunol; 2011 Apr; 41(4):963-73. PubMed ID: 21381021
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
[TBL] [Abstract][Full Text] [Related]
10. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.
Moncunill G; Armand-Ugón M; Clotet-Codina I; Pauls E; Ballana E; Llano A; Romagnoli B; Vrijbloed JW; Gombert FO; Clotet B; De Marco S; Esté JA
Mol Pharmacol; 2008 Apr; 73(4):1264-73. PubMed ID: 18182480
[TBL] [Abstract][Full Text] [Related]
12. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
[TBL] [Abstract][Full Text] [Related]
13. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of CXCR-4 and CCR-5 expression by interferon-gamma is associated with inhibition of chemotaxis and human immunodeficiency virus (HIV) replication but not HIV entry into human monocytes.
Creery D; Weiss W; Lim WT; Aziz Z; Angel JB; Kumar A
Clin Exp Immunol; 2004 Jul; 137(1):156-65. PubMed ID: 15196257
[TBL] [Abstract][Full Text] [Related]
15. Restricted replication of primary HIV-1 isolates using both CCR5 and CXCR4 in Th2 but not in Th1 CD4(+) T cells.
Vicenzi E; Panina-Bodignon P; Vallanti G; Di Lucia P; Poli G
J Leukoc Biol; 2002 Nov; 72(5):913-20. PubMed ID: 12429712
[TBL] [Abstract][Full Text] [Related]
16. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.
Cilliers T; Nhlapo J; Coetzer M; Orlovic D; Ketas T; Olson WC; Moore JP; Trkola A; Morris L
J Virol; 2003 Apr; 77(7):4449-56. PubMed ID: 12634405
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Bodart V; Anastassov V; Darkes MC; Idzan SR; Labrecque J; Lau G; Mosi RM; Neff KS; Nelson KL; Ruzek MC; Patel K; Santucci Z; Scarborough R; Wong RS; Bridger GJ; Macfarland RT; Fricker SP
Biochem Pharmacol; 2009 Oct; 78(8):993-1000. PubMed ID: 19540208
[TBL] [Abstract][Full Text] [Related]
18. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors.
Sabri F; Tresoldi E; Di Stefano M; Polo S; Monaco MC; Verani A; Fiore JR; Lusso P; Major E; Chiodi F; Scarlatti G
Virology; 1999 Nov; 264(2):370-84. PubMed ID: 10562499
[TBL] [Abstract][Full Text] [Related]
19. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
20. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
